<DOC>
	<DOCNO>NCT00123474</DOCNO>
	<brief_summary>This phase III study BMS-354825 subject chronic phase Philadelphia chromosome BCR-ABL positive chronic myelogenous leukemia , resistant intolerant imatinib mesylate ( Gleevec ) .</brief_summary>
	<brief_title>Chronic Myelogenous Leukemia ( CML ) - Follow : Study BMS-354825 Subjects With CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects Philadelphia chromosome positive ( Ph+ ) ( BCR/ABL+ ) chronic phase chronic myeloid leukemia whose disease primary acquire hematologic resistance imatinib mesylate intolerant imatinib mesylate . Men woman , 18 year old Adequate hepatic function Adequate renal function Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month least 3 month study manner risk pregnancy minimize . Women pregnant breastfeeding Subjects eligible willing undergo transplantation screen period A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy Uncontrolled significant cardiovascular disease Medications increase bleed risk Medications change heart rhythm Dementia alter mental status would prohibit understanding rendering informed consent History significant bleeding disorder unrelated CML Concurrent incurable malignancy CML Evidence organ dysfunction digestive dysfunction would prevent administration study therapy Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic Phase Chronic Myelogenous Leukemia</keyword>
</DOC>